Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 328Fallopian Tube Neoplasms 153Carcinoma, Ovarian Epithelial 115Endometrial Neoplasms 95Uterine Cervical Neoplasms 80Neoplasms 28Breast Neoplasms 27Peritoneal Neoplasms 24Brenner Tumor 24Carcinoma, Non-Small-Cell Lung 21Stomach Neoplasms 18Recurrence 17Neoplasm Metastasis 14Uterine Neoplasms 13Testicular Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Colorectal Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Melanoma 9Testicular Germ Cell Tumor 8Central Nervous System Neoplasms 8Urinary Bladder Neoplasms 7Triple Negative Breast Neoplasms 7Esophageal Neoplasms 7Carcinoma 7Prostatic Neoplasms 6Pancreatic Neoplasms 6Neurotoxicity Syndromes 6Carcinosarcoma 6

Interventions

camrelizumab 1Surgical Procedures, Operative 1Paclitaxel 1ON123300 1Letrozole 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrioid Endometrial Cancer × Paclitaxel × Gynecologic × Clear all
NCT06561308 2025-12-01

Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer

Women's Hospital School Of Medicine Zhejiang University

Phase 2 Recruiting
39 enrolled
Gynecologic

Endometrioid Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡